Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.

Bolognani F, Del Valle Rubido M, Squassante L, Wandel C, Derks M, Murtagh L, Sevigny J, Khwaja O, Umbricht D, Fontoura P.

Sci Transl Med. 2019 May 8;11(491). pii: eaat7838. doi: 10.1126/scitranslmed.aat7838. Epub 2019 May 1.

PMID:
31043521
2.

A Framework Proposal to Follow-Up on Preclinical Convulsive Signals of a New Molecular Entity in First-in-Human Studies Using Electroencephalographic Monitoring.

Abt M, Dinklo T, Rothfuss A, Husar E, Dannecker R, Kallivroussis K, Peck R, Doessegger L, Wandel C.

Clin Pharmacol Ther. 2019 Apr 16. doi: 10.1002/cpt.1455. [Epub ahead of print] Review.

PMID:
30993670
3.

First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I.

Kletzl H, Guenther A, Höflich A, Höflich C, Frystyk J, Staack RF, Schick E, Wandel C, Bleich N, Metzger F.

Growth Horm IGF Res. 2017 Apr;33:9-16. doi: 10.1016/j.ghir.2017.01.001. Epub 2017 Jan 10.

PMID:
28110155
4.

Erratum to: Clinical trial considerations on male contraception and collection of pregnancy information from female partner: update.

Banholzer ML, Wandel C, Barrow P, Mannino M, Schmitt G, Guérard M, Müller L, Greig G, Amemiya K, Peck R, Singer T, Doessegger L.

Clin Transl Med. 2016 Dec;5(1):30. doi: 10.1186/s40169-016-0115-4. Epub 2016 Aug 12. No abstract available.

5.

Clinical trial considerations on male contraception and collection of pregnancy information from female partner: update.

Banholzer ML, Wandel C, Barrow P, Mannino M, Schmitt G, Guérard M, Müller L, Greig G, Amemiya K, Peck R, Singer T, Doessegger L.

Clin Transl Med. 2016 Dec;5(1):23. doi: 10.1186/s40169-016-0103-8. Epub 2016 Jul 25. Erratum in: Clin Transl Med. 2016 Dec;5(1):30.

6.

Population prevalence of Down's syndrome in the United Kingdom.

Alexander M, Ding Y, Foskett N, Petri H, Wandel C, Khwaja O.

J Intellect Disabil Res. 2016 Sep;60(9):874-8. doi: 10.1111/jir.12277. Epub 2016 Mar 28.

PMID:
27018385
7.

Morbidity and medication in a large population of individuals with Down syndrome compared to the general population.

Alexander M, Petri H, Ding Y, Wandel C, Khwaja O, Foskett N.

Dev Med Child Neurol. 2016 Mar;58(3):246-54. doi: 10.1111/dmcn.12868. Epub 2015 Aug 18.

8.

Clinical trial considerations on male contraception and collection of pregnancy information from female partners.

Banholzer ML, Buergin H, Wandel C, Schmitt G, Gocke E, Peck R, Singer T, Reynolds T, Mannino M, Deutsch J, Doessegger L.

J Transl Med. 2012 Jun 21;10:129. doi: 10.1186/1479-5876-10-129.

9.

Nursing interventions to improve the health of men with prostate cancer undergoing radiotherapy: a review.

Tärnhuvud M, Wändel C, Willman A.

Eur J Oncol Nurs. 2007 Sep;11(4):328-39. Epub 2007 Apr 6. Review.

PMID:
17409023
10.

"Inactive" excipients such as Cremophor can affect in vivo drug disposition.

Wandel C, Kim RB, Stein CM.

Clin Pharmacol Ther. 2003 May;73(5):394-6. No abstract available.

PMID:
12732839
11.
12.

Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects.

Stein CM, Sadeque AJ, Murray JJ, Wandel C, Kim RB, Wood AJ.

Clin Pharmacol Ther. 2001 May;69(5):317-23.

PMID:
11371999
13.

Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers.

Stass H, Wandel C, Delesen H, Möller JG.

Clin Pharmacokinet. 2001;40 Suppl 1:27-32.

PMID:
11352439
14.

Increased drug delivery to the brain by P-glycoprotein inhibition.

Sadeque AJ, Wandel C, He H, Shah S, Wood AJ.

Clin Pharmacol Ther. 2000 Sep;68(3):231-7.

PMID:
11014404
15.

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.

Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR.

Clin Pharmacol Ther. 2000 Jul;68(1):82-91.

PMID:
10945319
16.

Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.

Wandel C, Kim RB, Guengerich FP, Wood AJ.

Drug Metab Dispos. 2000 Aug;28(8):895-8.

PMID:
10901697
17.

Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.

Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB.

Drug Metab Dispos. 2000 Jun;28(6):655-60.

PMID:
10820137
18.

P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.

Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ.

Cancer Res. 1999 Aug 15;59(16):3944-8.

19.

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR.

Pharm Res. 1999 Mar;16(3):408-14.

PMID:
10213372
20.

Effect of CYP3A inhibition on vesnarinone metabolism in humans.

Wandel C, Lang CC, Cowart DC, Girard AF, Bramer S, Flockhart DA, Wood AJ.

Clin Pharmacol Ther. 1998 May;63(5):506-11.

PMID:
9630823
21.

Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally.

Wandel C, Böcker RH, Böhrer H, deVries JX, Hofmann W, Walter K, Kleingeist B, Neff S, Ding R, Walter-Sack I, Martin E.

Drug Metab Dispos. 1998 Feb;26(2):110-4.

PMID:
9456296
22.

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR.

J Clin Invest. 1998 Jan 15;101(2):289-94.

23.

The relationship between cytochrome P4502E1 activity and plasma fluoride levels after sevoflurane anesthesia in humans.

Wandel C, Neff S, Keppler G, Böhrer H, Stockinger K, Wilkinson GR, Wood M, Martin E.

Anesth Analg. 1997 Oct;85(4):924-30.

PMID:
9322481
24.

[A comparative study of the use of sevoflurane and propofol in ambulatory surgery].

Motsch J, Wandel C, Neff S, Martin E.

Anaesthesist. 1996 Feb;45 Suppl 1:S57-62. German.

PMID:
8775105
25.

Rifampicin and cyclosporine dosing in heart transplant recipients.

Wandel C, Böhrer H, Böcker R.

J Cardiothorac Vasc Anesth. 1995 Oct;9(5):621-2. No abstract available.

PMID:
8547575
26.

Lignocaine metabolite formation: an indicator for liver dysfunction and predictor of survival in surgical intensive care patients.

Schröter J, Wandel C, Böhrer H, Schmidt H, Böttiger BW, Martin E.

Anaesthesia. 1995 Oct;50(10):850-4.

27.

Recovery characteristics following anaesthesia with sevoflurane or propofol in adults undergoing out-patient surgery.

Wandel C, Neff S, Böhrer H, Browne A, Motsch J, Martin E.

Eur J Clin Pharmacol. 1995;48(3-4):185-8.

PMID:
7589039
28.

Midazolam is metabolized by at least three different cytochrome P450 enzymes.

Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E.

Br J Anaesth. 1994 Nov;73(5):658-61.

29.

[The importance of the cytochrome P-450 superfamily in the metabolism of an anesthesia relevant drug].

Wandel C, Böhrer H, Böcker R.

Anasthesiol Intensivmed Notfallmed Schmerzther. 1993 Dec;28(8):511-6. Review. German. No abstract available.

PMID:
8292705

Supplemental Content

Loading ...
Support Center